Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 1.10B | 919.69M | 776.05M | 569.14M | 302.32M | 50.24M |
Gross Profit | 429.62M | 363.01M | 372.27M | 303.29M | 153.69M | 21.22M |
EBITDA | -19.20M | 122.52M | 101.88M | 95.99M | 21.27M | -495.00K |
Net Income | -128.62M | 32.61M | 82.00K | 19.07M | -30.69M | -2.62M |
Balance Sheet | ||||||
Total Assets | 2.02B | 1.81B | 1.41B | 1.32B | 1.26B | 262.73M |
Cash, Cash Equivalents and Short-Term Investments | 98.89M | 131.67M | 43.42M | 48.91M | 61.92M | 86.89M |
Total Debt | 569.76M | 425.09M | 426.28M | 358.42M | 401.94M | 23.57M |
Total Liabilities | 1.03B | 877.55M | 563.16M | 503.78M | 554.37M | 43.75M |
Stockholders Equity | 826.20M | 867.61M | 767.67M | 732.34M | 618.24M | 217.37M |
Cash Flow | ||||||
Free Cash Flow | -17.33M | -6.70M | 37.20M | 70.14M | 19.59M | -6.52M |
Operating Cash Flow | 3.93M | 9.52M | 66.44M | 76.55M | 22.27M | -5.38M |
Investing Cash Flow | -86.18M | -60.23M | -106.42M | -37.93M | -499.78M | -44.21M |
Financing Cash Flow | 133.09M | 133.50M | 10.63M | -52.85M | 452.53M | 120.84M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
61 Neutral | 30.56M | 184.21 | 7.55% | ― | 11.89% | 5.56% | |
61 Neutral | 1.68B | -35.87 | -2.55% | 0.59% | 9.94% | 35.48% | |
59 Neutral | 269.31M | 2.09 | 105.57% | 2.47% | -35.35% | 948.72% | |
53 Neutral | 206.22M | -110.81 | -2.09% | 0.61% | -0.16% | 75.25% | |
46 Neutral | C$1.29B | 30.45 | -14.61% | ― | 20.36% | -186.10% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
WELL Health Technologies Corp reported record financial results for Q2-2025, achieving a 57% increase in quarterly revenues to $356.7 million, driven by organic growth and acquisitions. The company also marked its first-ever quarter with over 1 million patient visits in Canada, reflecting a 38% year-over-year growth. WELL’s strategic investments in Canadian clinics and technology have led to improved provider productivity and significant milestones in financial metrics, including Adjusted EBITDA and net income. The inclusion of HEALWELL AI contributed $40.5 million to revenue, and the company is considering strategic alternatives for its U.S. assets to focus on core Canadian operations.
The most recent analyst rating on (TSE:WELL) stock is a Buy with a C$6.00 price target. To see the full list of analyst forecasts on WELL Health Technologies Corp stock, see the TSE:WELL Stock Forecast page.
WELL Health Technologies Corp. announced it will release its second quarter 2025 financial results on August 14, 2025. The company will hold a conference call and webcast to discuss the results, led by CEO Hamed Shahbazi and CFO Eva Fong. This announcement reflects WELL’s ongoing commitment to transparency and engagement with stakeholders, as it continues to expand its influence in the digital healthcare industry.
The most recent analyst rating on (TSE:WELL) stock is a Buy with a C$6.00 price target. To see the full list of analyst forecasts on WELL Health Technologies Corp stock, see the TSE:WELL Stock Forecast page.